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Guideline on the use of
onabotulinumtoxinA in chronic migraine: a
consensus statement from the European
Headache Federation
Lars Bendtsen1* , Simona Sacco2, Messoud Ashina1, Dimos Mitsikostas3, Fayyaz Ahmed4, Patricia Pozo-Rosich5,6
and Paolo Martelletti7
Abstract
OnabotulinumtoxinA is being increasingly used in the management of chronic migraine (CM). Treatment with
onabotulinumtoxinA poses challenges compared with traditional therapy with orally administered preventatives.
The European Headache Federation identified an expert group that was asked to develop the present guideline to
provide recommendations for the use of onabotulinumtoxinA in CM. The expert group recommend onabotulinumtoxinA
as an effective and well-tolerated treatment of CM. Patients should preferably have tried two to three other
migraine prophylactics before start of onabotulinumtoxinA. Patients with medication overuse should be withdrawn
from the overused medication before initiation of onabotulinumtoxinA if feasible, if not onabotulinumtoxinA can be
initiated from the start or before withdrawal. OnabotulinumtoxinA should be administered according to the PREEMPT
injection protocol, i.e. injecting 155 U–195 U to 31–39 sites every 12-weeks. We recommend that patients are defined
as non-responders, if they have less than 30% reduction in headache days per month during treatment with
onabotulinumtoxinA. However other factors such as headache intensity, disability and patient preferences
should also be considered when evaluating response. Treatment should be stopped, if the patient does not
respond to the first two to three treatment cycles. Response to continued treatment with onabotulinumtoxinA should
be evaluated by comparing the 4 weeks before with the 4 weeks after each treatment cycle. It is recommended that
treatment is stopped in patients with a reduction to less than 10 headache days per month for 3 months and that
patients are re-evaluated 4–5 months after stopping onabotulinumtoxinA to make sure that the patient has
not returned to CM. Questions regarding efficacy and tolerability of onabotulinumtoxinA could be answered
on the basis of scientific evidence. The other recommendations were mainly based on expert opinion. Future
research on the treatment of CM with onabotulinumtoxinA may further improve the management of this
highly disabling disorder.
Keywords: Chronic migraine, OnabotulinumtoxinA, Management, Guideline
* Correspondence: lars.bendtsen@regionh.dk
1Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup,
Faculty of Health and Medical Sciences, University of Copenhagen, 2600
Glostrup, Denmark
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Bendtsen et al. The Journal of Headache and Pain  (2018) 19:91 
https://doi.org/10.1186/s10194-018-0921-8
Introduction
Chronic migraine (CM) is a debilitating disorder affecting
approximately 2% of the general population [1] and is very
common in specialised headache centres. CM is defined
as headache occurring on ≥15 days per month for >
3 months of which ≥8 days has the features of migraine
headache [2]. Only two treatments have demonstrated
efficacy in CM: onabotulinumtoxinA and topiramate [3].
Possible efficacy of onabotulinumtoxinA in migraine was
incidentally noted in patients treated cosmetically for wrin-
kles. In 2010, onabotulinumtoxinA was reported effective
for the treatment of CM in the Phase 3 Research Evaluating
Migraine Prophylaxis Therapy (PREEMPT) trials [4, 5] and
was approved both by the European Medicines Agency and
by the US Food and Drug Administration for the prophy-
laxis of CM. Its use was endorsed by the National Institute
for Health and Care Excellence (NICE) in 2012 [6]. Onabo-
tulinumtoxinA has not been found effective in episodic mi-
graine or in tension-type headache [7]. The mode of action
of onabotulinumtoxinA in CM may include modulation of
neurotransmitter release, changes in surface expression of
receptors and cytokines as well as enhancement of opioi-
dergic transmission [8]. It is likely that onabotulinumtoxinA
reduces both peripheral and central sensitization in CM
through such mechanisms [7, 9].
Since its approval, the use of onabotulinumtoxinA has
increased considerably. Treatment with onabotulinum-
toxinA poses challenges compared with traditional ther-
apy with orally administered preventatives for headache
specialists not used to injecting toxins. Due to the ab-
sence of European Guidelines for the use of onabotuli-
numtoxinA, the European Headache Federation has
considered the need to write a Guideline for the use of
onabotulinumtoxinA in CM.
The aim of this guideline is to provide recommenda-
tions for the use of onabotulinumtoxinA in CM.
Methods
The EHF identified an expert panel consisting of seven
members. We have developed recommendations for a
series of questions that are essential for daily clinical use
of onabotulinumtoxinA in CM, which are based on the
available evidence and our clinical experience.
We have answered the following questions:
1. Is onabotulinumtoxinA effective and well-tolerated
for the treatment of CM?
2. When should onabotulinumtoxinA be offered?
3. Should withdrawal be performed before treatment
with onabotulinumtoxinA in patients with CM and
medication-overuse?
4. How should the treatment be administered?
5. When can a de novo patient be considered non-
responder to onabotulinumtoxinA?
6. How should responders to onabotulinumtoxinA be
managed over time?
In the discussion section we have summarized our
findings and added some general considerations.
The Grading of Recommendations, Assessment, De-
velopment and Evaluation (GRADE) system has been
endorsed by the European Academy of Neurology [10]
as the method of choice to establish recommendations
and was used here if possible as was the Patients; Inter-
vention; Comparison and Outcome (PICO) [10] method.
Final quality of evidence was rated as high, moderate,
low or very low based on study design, study limitations,
inconsistency, indirectness, imprecision, publication bias,
effect size, dose response and confounding. Strength
(strong or weak) and direction (for or against) of recom-
mendation were determined on basis of balance between
desirable and undesirable effects, quality of evidence,
values and preferences and costs [10]. With our present
scientific evidence this could only be used for the first
question. If GRADE was not applicable, an ungraded
good practice statement was given, according to the
available level of evidence. The Delphi method was used
to reach consensus.
Search strategy and results
Papers published in peer-reviewed journals were identi-
fied using PubMed/Medline, EMBASE and Cochrane Li-
brary. Search was done with unrestricted date of start
and until April 2018 and restricted to English language.
We searched for prospective studies investigating effi-
cacy, safety or tolerability of onabotulinumtoxinA in CM
compared with placebo or other prophylactic treatments
and for prospective observational studies published in
peer-reviewed journals. We excluded retrospective stud-
ies, studies not performed according to PREEMPT, stud-
ies of poor quality, e.g. studies with insufficient
reporting of diagnostic criteria or outcome and reviews.
We initially identified 823 studies which were finally
reduced to 27 studies. Please see Fig. 1. The retrieved
studies were all considered for question 1. For the fol-
lowing questions search was performed among the re-
trieved studies.
Recommendations
Question 1: For patients with CM is treatment with
onabotulinumtoxinA effective and well-tolerated?
PICO:
Population: patients with CM with or without
medication overuse
Intervention: onabotulinumtoxinA 155 U to 195 U
Comparison: placebo or other prophylactic treatments
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Outcome: meaningful reduction of headache days (> 30%
from baseline) with acceptable side-effects
Search strategy and results
We identified two randomized placebo-controlled multi-
centre trials, the PREEMPT 1 [4] and PREEMPT 2 [5]
(Phase 3 Research Evaluating Migraine Prophylaxis Ther-
apy) clinical trials. Both trials consisted of a 24-week
placebo-controlled phase followed by a 32-week open-label
extension phase. OnabotulinumtoxinA was administered at
12-week intervals. OnabotulinumtoxinA was injected in 31
sites (5 U per injection) with possibility for additional 8 in-
jections according to a “follow-the pain” strategy. The total
dose of onabotulinumtoxinA was 155 U to 195 U injected
in 31 to 39 sites. This is hereafter referred to as the PRE-
EMPT injection protocol. A total of 1384 patients received
onabotulinumtoxinA or placebo. Approximately two-thirds
of CM patients were overusing headache medications at
baseline. There was no significant effect on the primary
endpoint, headache episodes, in the PREEMPT 1 trial,
while there was a significant effect on headache and mi-
graine days. The PREEMPT 2 trial met its primary end-
point headache days. The results of the PREEMPT 1 and 2
trials have been evaluated in a pooled analysis [11]. The
pooled analysis reported a large decrease from baseline in
headache days, but due to a large placebo-effect, the effi-
cacy of onabotulinumtoxinA over placebo was modest (−
8.4 vs. -6.6 days per 4 weeks, P < 0.01) [11]. Responder rate,
defined as percentage of patients with a decrease in fre-
quency of headache days from baseline of at least 50%, was
47.1% vs. 35.1% (P < 0.001). Post-hoc analysis demonstrated
that 71.4, 9.4 and 5.4% of patients responded to treatment
cycles 1, 2 and 3 respectively using 30% reduction of head-
ache days compared with baseline as responder rate [12].
Fig. 1 Process of identifying eligible studies for the guideline
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OnabotulinumtoxinA was also significantly more effective
in reducing a number of secondary efficacy variables in-
cluding disability. The Headache Impact Test (HIT)-6 score
was reduced by 4.8 by onabotulinumtoxinA compared with
2.4 by placebo (P < 0.001). Post-hoc analyses demonstrated
that headache intensity was reduced in non-responders (pa-
tients with less than 50% reduction in headache frequency)
[13] and that quality of life was still improved after 1 year
of treatment [14]. OnabotulinumtoxinA was well tolerated,
the most common adverse events compared with placebo
were neck pain (6.7% vs. 2.2%), muscular weakness (5.5%
vs. 0.3%), eyelid ptosis (3.3% vs. 0.3%) and injection-site
pain (3.2% vs. 2.0%). Discontinuation rates due to adverse
events were low (3.8% vs. 1.2%). A secondary analysis of the
PREEMPT study investigating the subgroup of patients
(1005 out of 1384) who received all 5 treatment cycles
demonstrated continued efficacy and tolerability of onabo-
tulinumtoxinA [15].
A subgroup analysis of 904 patients with medication
overuse from the PREEMPT studies found similar effect
in patients with and without medication overuse [16].
When evaluating these data it should be noted that they
were obtained from post hoc analysis [17]. The same
was found in a UK study comparing efficacy of onabotu-
linumtoxinA administered according to PREEMPT in
219 patients with and 215 patients without medication
overuse [18].
The good safety and tolerability profile of onabotuli-
numtoxinA was confirmed in a pooled analysis [19] of
two phase 2 studies in chronic daily headache [20, 21]
and the two PREEMPT studies [4, 5]. Furthermore, a
sub-analysis of 513 subjects receiving all 5 treatment cy-
cles in the PREEMPT studies found that adverse events
decreased over time [19].
We identified a number of prospective open-label
studies evaluating efficacy and safety of onabotulinum-
toxinA [22–39]. In general these studies were long-term
studies treating CM patients with and without medica-
tion overuse according to the PREEMPT protocol. Sev-
eral of the studies are limited by some methodological
flaws [40]. These studies consistently reported positive
results regarding both efficacy and tolerability in line
with the PREEMPT studies. A UK study including 254
patients reported responder rates of 32% and 47% when
response was defined as ≥50% and ≥ 30% reduction in
headache days, respectively [30]. A large multinational
study including 1160 patients confirmed the positive
safety profile of onabotulinumtoxinA [41]. Longest
follow-up reported was in the multinational Chronic mi-
graine OnabotulinuMtoxinA Prolonged Efficacy open
Label (COMPEL) study [23], which included 716
patients of whom 373 completed the 2 years follow-up.
A randomized controlled study reported better efficacy
of acupuncture than of onabotulinumtoxinA and low-
dose valproate [33]. Two studies reported comparable
efficacy of onabotulinumtoxinA and topiramate [42, 43]
with fewer adverse events from onabotulinumtoxinA
[43]. The latter is supported by clinical experience.
Further evidence is under way through the REsource
utilisation and Patient-reported OutcomeS (REPOSE)
studies [44].
Clinical guide
The blinding of the PREEMPT studies has been criti-
cized, because injections in the forehead removing
wrinkling could cause un-blinding [6, 7]. In an older
study 70% and 60% of patients who knew that they had
a 50% chance of receiving placebo, correctly guessed that
they were treated with active drug after the first and
third treatment cycles respectively [20]. According to
GRADE (Table 1) the quality of the PREEMPT studies
regarding efficacy is moderate due to risk of un-blinding,
while it is high regarding safety because of the very posi-
tive safety profile. The high placebo response in the
PREEMPT studies [11] and the long-term effect of ona-
botulinumtoxinA [23] speak against placebo being a
major factor.
Prospective open-label observational studies have ser-
ious limitations regarding evaluation of efficacy includ-
ing lack of control group, risk of publication bias and a
potentially high placebo-response. However, the results
from the studies are quite consistently positive and sup-
port the findings from the placebo-controlled PREEMPT
studies. In addition they provide important information
on efficacy and tolerability of long-term treatment with
onabotulinumtoxinA.
Table 1 GRADE evaluation of placebo-controlled studies evaluating efficacy and tolerability of onabotA
Studies
(participants)
Outcome Comparison Type Quality Effect
size
GRADE quality
of evidence
Direction Strength Comment
Dodick (1384) Headache days OnabotA 155 U–195 U
versus placebo
R −1 0 Moderate For Strong Quality points deducted for risk
of bias (−1)
Diener (2436) Adverse events OnabotA 75 U–260 U
versus placebo
R -1 + 1 High For Strong Quality points deducted for risk
of bias (−1). Effect size point
added for small frequency of AE
The Dodick paper [11] was a pooled analysis of the Aurora [4] and 2010 Diener [5] studies. The 2014 Diener paper [19] was a pooled analysis of two phase 2
studies in chronic daily headache [20, 21] and the two PREEMPT studies [4, 5]. Type: R randomized controlled trial
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Taking the collected evidence from the PREEMPT
studies, the observational studies and clinical experience
into consideration, the final quality of evidence is con-
sidered to be high regarding both efficacy and safety of
onabotulinumtoxinA. The effect size in average is con-
sidered modest compared with placebo. However, aver-
age group differences in efficacy cannot be considered in
isolation as this may obscure meaningful individual pa-
tient differences. Direction of recommendation for use
of onabotulinumtoxinA is for and strength of recom-
mendation is strong. Quality of evidence for comparison
of onabotulinumtoxinA with other prophylactic treat-
ments is too low to make final conclusions, but it is pos-
sible that the effect size is comparable to that of
topiramate but with a better tolerability profile.
Final recommendation
OnabotulinumtoxinA is recommended for treatment of
patients with CM and considered an effective and well-
tolerated treatment. Quality of evidence: high. Strength
of the recommendation: strong.
Clinical question 2: For patients with CM when should
onabotulinumtoxinA be offered?
Search strategy and results
Among the retrieved studies, we searched for reports evalu-
ating how onabotulinumtoxinA candidates should be se-
lected. We identified the following relevant questions:
How many prophylactics should have failed before ona-
botulinumtoxinA is administered? NICE performed a
subgroup analysis of efficacy related to previous treat-
ment with prophylactic medications. They found that
onabotulinumtoxinA was equally effective in patients
who had previously received one, two or three or more
preventive treatments [6]. Based on cost-effectiveness in
the UK, NICE recommends that patients should have
failed three or more other migraine prophylactics before
onabotulinumtoxinA is administered [6].
Is it possible to predict who will be good responders? It
has been reported that short disease duration [28, 32]
and high serum levels of calcitonin gene-related peptide
(CGRP) [27] are predictors of good outcome to
onabotulinumtoxinA.
Clinical guide
Taking costs into consideration, failure of at least three
migraine prophylactics before onabotulinumtoxinA is
administered is recommended by NICE. However, this
may not apply to all countries, and some experts recom-
mend initiation of onabotulinumtoxinA after failure of
at least two to three prophylactics, because topiramate is
the only other drug with proved efficacy in CM and be-
cause of the better tolerability profile of onabotulinum-
toxinA. We recommend that patients should have failed
(lack of effect or intolerable side-effects) two to three or
more other migraine prophylactics before onabotuli-
numtoxinA is administered. However, in some patients
this is not possible due to multiple comorbid disorders,
e.g., cardiac disorder, overweight or depression. Some
data indicate that patients who are treated earlier have a
better response. However, early stage CM may be more
likely to undergo spontaneous fluctuations and/or to im-
prove spontaneously than later stage CM. Yet, there are
not enough data to select CM patients to be or not to be
treated with onabotulinumtoxinA based on clinical or la-
boratory characteristics.
Final recommendation
It is recommended that patients should have failed at
least two to three other migraine prophylactics unless
contraindicated by comorbid disorders before onabotuli-
numtoxinA is administered. This recommendation is
based on expert opinion.
Question 3: For patients with CM plus medication-overuse
should withdrawal be done before treatment with
onabotulinumtoxinA is initiated?
Search strategy and results
Among the retrieved studies we searched for reports
comparing treatment with onabotulinumtoxinA initiated
before as compared with after withdrawal of the over-
used medication in patients with CM plus medication
overuse. We found no such studies.
Clinical guide
There is general consensus that CM patients with medi-
cation overuse should be withdrawn from the overused
medication (detoxified) [6, 17] but not how this should
be done. Evidence indicate that detoxification both with
onabotulinumtoxinA [16, 18], detoxification with or
without oral prophylactics from the start [45], and de-
toxification with delayed prophylactic treatment after 2
months [46] are all effective. Because of differences in,
e.g., study design and patients characteristics, it is not
possible to compare efficacy among these studies. Con-
sidering that not all patients need prophylactics after de-
toxification [47], it is recommended to detoxify first with
later initiation of onabotulinumtoxinA when possible.
This is in accordance with recommendations from
(NICE) [6]. If this is not possible, onabotulinumtoxinA
can be initiated from the start or even before withdrawal
of the overused medication.
Final recommendation
In patients with CM and medication overuse, it is prefer-
able to detoxify first with later initiation of onabotuli-
numtoxinA. If this is not feasible, onabotulinumtoxinA
can be initiated from the start or even before withdrawal
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of the overused medication. This recommendation is
based on expert opinion.
Clinical question 4: How should treatment with
onabotulinumtoxinA be administered?
Search strategy and results
Among the retrieved studies, we searched for reports
evaluating administration of onabotulinumtoxinA.
The PREEMPT injection protocol, i.e. injection of 155 U–
195 U administered to 31–39 sites every 12-weeks as previ-
ously described, set the standard for treatment with onabotu-
linumtoxinA in CM. It has been argued that an injection
paradigm customized to the individual patient would be
preferable [48]. However, we found no studies comparing
the PREEMPT protocol with an alternative protocol.
Treatment with 155 U and 195 U has not been compared
head to head. In an open label prospective study, Negro et
al. [35] reported higher effect of 195 U than of 155 U given
in an earlier study from the same study group.
Clinical guide
The PREEMPT injection protocol should be followed,
since it is the only protocol that has proved efficacy of
onabotulinumtoxinA. It is possible that 195 U is more
effective than 155 U. The higher dose could be consid-
ered, if the patient does not respond to 155 U.
Final recommendation
OnabotulinumtoxinA should be administered according
to the PREEMPT injection protocol. This recommenda-
tion is based on evidence from the PREEMPT trials.
Clinical question 5: When can a de novo patient be
considered non-responder to onabotulinumtoxinA?
Search strategy and results
Among the retrieved studies, we searched for reports
evaluating when patients previously naïve to onabotuli-
numtoxinA can be considered non-responders.
In the PREEMPT studies responders were defined as
patients with at least 50% reduction in headache days
per month, while NICE defined responders as patients
having at least 30% reduction in headache days per
month [6]. Like in other chronic pain conditions [49],
most headache experts regard a 30% reduction in head-
ache days for clinically relevant in a complicated dis-
order as CM [12, 50]. Khalil et al. [30] suggested that
responders should be defined as either 50% or more re-
duction in headache or migraine days or doubling of
headache-free days (“crystal clear days”) provided that
there was at least 3 headache-free days at baseline. Other
experts consider a < 30% reduction in headache days as
response, if it is accompanied by improvement of other
variables such as reduction in headache intensity or im-
provement of quality of life [50].
A pooled sub-analysis of the PREEMPT studies re-
ported that among onabotulinumtoxinA treated patients
49.3, 11.3 and 10.3% of the patients responded for the
first time (50% responders) during treatment cycles 1, 2
and 3 respectively [12]. These data were not tested
against placebo. The authors suggested that patients
should be offered 2–3 treatment cycles before being
categorised as non-responders. Prospective open-label
studies reported increased efficacy over 5–9 treatment
cycles [35, 38]. NICE recommends that treatment should
be stopped if the patient does not respond with at least
30% reduction in headache days per month after two
treatment cycles [6].
Clinical guide
Response to onabotulinumtoxinA should be continu-
ously monitored by headache calendars. The definition
of responders to onabotulinumtoxinA is important for
daily clinical practice, but there are currently no convin-
cing data supporting one definition over another. We
recommend the use of the definition most easy to use,
i.e. that patients should be defined as non-responders, if
they have less than 30% reduction in headache days dur-
ing the first month after treatment with onabotulinum-
toxinA compared with the month before first treatment.
However, other factors such as headache intensity, dis-
ability and patient preferences should also be considered.
Treatment should be stopped if the patient does not re-
spond to onabotulinumtoxinA during the first 2–3 treat-
ment cycles (negative stopping rule).
Final recommendation
It is recommended that patients should be defined as
non-responders, if they have less than 30% reduction in
headache days per month during treatment with onabo-
tulinumtoxinA. However, other factors such as headache
intensity, disability and patient preferences should also
be considered. Treatment should be stopped, if the pa-
tient does not respond to the first 2–3 treatment cycles.
This recommendation is based on expert opinion.
Clinical question 6: How should responders to
onabotulinumtoxinA be managed over time?
Search strategy and results
Among the retrieved studies, we searched for reports in-
vestigating when treatment with onabotulinumtoxinA
should be stopped once started and how the patients
should be managed over time. We found no such studies.
Clinical guide
Response to onabotulinumtoxinA should be continuously
monitored by headache calendars, where patients record
headache days and intake of acute headache medications.
Available evidence indicate that electronic calendars,
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accessible via mobile technologies, may ensure better data
recording [45].
There is no generally accepted agreement on from
which time point’s response to onabotulinumtoxinA
should be evaluated during continued treatment. We
suggest that the 4 weeks before and 4 weeks after each
treatment cycle should be compared.
NICE recommends that treatment with onabotulinum-
toxinA is stopped if the patient has reverted to episodic
migraine for three consecutive months [6] (positive stop-
ping rule). This may be impractical in many clinics, be-
cause it can be impossible to offer the patient a fast
appointment if migraine reverts to CM due to lack of re-
sources. The delay may result in worsening of headache
and decreased quality of life [50]. The natural fluctua-
tions occurring over time in CM [51] should also be
taken into account. It has been proposed that onabotuli-
numtoxinA is stopped only in patients with a reduction
to less than 10 headache days per month for 3 months
given that those with a higher frequency carry a higher
risk of relapse to CM [7]. Others have recommended
that only in those subjects who are stable responders to
onabotulinumtoxinA for at least 1 year, the extension of
the inter-injection interval may be a responsible strategy
to verify whether the improvement is a long-lasting re-
mission of the disease or attenuation of symptoms due
to onabotulinumtoxinA treatment [40].
We recommend that patients are re-evaluated 4–
5 months after stopping onabotulinumtoxinA to make
sure that the patient has not returned to CM.
Final recommendations
It is recommended to evaluate the response to continued
treatment with onabotulinumtoxinA on the basis of
headache calendars by comparing the 4 weeks before
and 4 weeks after each treatment cycle. We recommend
to stop treatment in patients with a reduction to less
than 10 headache days per month for 3 months. How-
ever, other factors such as headache intensity, disability
and patient preferences should also be considered. Pa-
tients should be re-evaluated 4–5 months after stopping
onabotulinumtoxinA to make sure that the patient has
not returned to CM. These recommendations are based
on expert opinion.
Discussion
OnabotulinumtoxinA is recommended as an effective
and well-tolerated treatment of CM. Patients should
preferably have tried 2–3 other migraine prophylactics
before start of onabotulinumtoxinA. However, many CM
patients bear a considerable load of co-morbidities [52].
This can make it challenging to choose oral prophylac-
tics, since many of these are contraindicated in the pres-
ence of, e.g., cardiovascular disease, depression or
obesity. Treatment with oral prophylactics is often fur-
ther complicated by poor tolerability, resulting in low
persistence to oral prophylactic treatment in migraineurs
[53]. If the patient has some, but insufficient, effect of
oral prophylactics, these can go hand in hand with ona-
botulinumtoxinA if needed.
Management of concomitant medication overuse is
controversial and differs considerably among headache
centres and countries. At present we have no robust data
that favours one approach over another. We recommend
that patients with medication overuse should be with-
drawn from the overused medication before initiation of
onabotulinumtoxinA if feasible, if not onabotulinumtox-
inA can be initiated from the start or before withdrawal.
Before the PREEMPT studies, onabotulinumtoxinA
was administered according to highly variable protocols
in the published reports, e.g. with different doses, num-
ber of injection sites and intervals between treatment cy-
cles, resulting in inconsistent results. We recommend
that onabotulinumtoxinA is administered according to
the PREEMPT injection protocol, i.e. injecting 155 U–
195 U to 31–39 sites every 12-weeks, because this is the
only treatment paradigm that has scientifically proved to
be effective. It is possible that 195 U is more effective
than 155 U. The higher dose could be considered, if the
patient does not respond to 155 U.
The success of treatment depends not only on how
onabotulinumtoxinA is administered but also on how
the patient is treated in other aspects. Patients should be
educated about their condition and how onabotulinum-
toxinA is administered. Patients should be given realistic
expectations, i.e. they should be told that the treatment
may be able to reduce frequency and intensity of their
migraine, but that it does not cure migraine. They
should be told that effect usually is seen within 3–7 days,
that the effect may wear off before the next treatment
cycle, and that response should be evaluated by contin-
ued use of headache calendars.
Evaluation of response to migraine treatment is com-
plex, because it involves not only frequency but also se-
verity of headaches, tolerability of the treatment,
disability and patient preferences. All of these factors
should be taken into consideration when evaluating the
response to onabotulinumtoxinA. However, there are no
robust data showing which of these variables that best
quantifies response to onabotulinumtoxinA. Further-
more, it is impractical for the patients to have to record
many variables over a prolonged period of time. We
therefore recommend that the simplest measure, head-
ache days, is used as a minimum to monitor response.
Other measures such as HIT-6 can be added. We rec-
ommend that patients are defined as non-responders, if
they have less than 30% reduction in headache days per
month during treatment with onabotulinumtoxinA, and
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that treatment should be stopped, if the patient does not
respond to the first 2–3 treatment cycles.
For initial responders to onabotulinumtoxinA, continued
evaluation of response is complicated by the fact that the
effect of treatment wears off after some time, typically 2–
3 months, so which time points should the evaluation be
based on? To complicate it more, most responders will not
fulfil the criteria for CM when successfully treated, because
they will not have had CM for more than 3 months when
they show up for the next treatment cycle. So when should
treatment be stopped? There are no robust data to guide us
on these questions. We recommend that response to con-
tinued treatment with onabotulinumtoxinA is evaluated by
comparing the 4 weeks before and 4 weeks after each treat-
ment cycle. It is recommended that treatment is stopped in
patients with a reduction to less than 10 headache days per
month for 3 months and that patients are re-evaluated 4–
5 months after stopping onabotulinumtoxinA to make sure
that the patient has not returned to CM.
Cost-effectiveness of treatment with onabotulinumtox-
inA is an important issue both for the individual and for
society. NICE have calculated that treatment with onabo-
tulinumtoxinA is cost-effective, if certain inclusion criteria
and stopping rules are adhered to [6]. Likewise, reports
from Italy [54], the US [55] and UK [56, 57] claim onabo-
tulinumtoxinA to be cost effective. However, due to the
highly variable health care systems in the European coun-
tries, it is not possible for us to give general evaluations on
the cost-effectiveness of onabotulinumtoxinA.
Conclusions and recommendations for future
research
The experts in the present panel are confident that ona-
botulinumtoxinA has an important role in the manage-
ment of CM provided that the recommendations in this
guideline are followed. However, only the first of the
clinical questions in this guideline, regarding efficacy
and tolerability of onabotulinumtoxinA, could be an-
swered on the basis of scientific evidence.
There is a need for studies investigating the role of ona-
botulinumtoxinA in relation to other prophylactics, includ-
ing the future calcitonin-gene-related-peptide receptor
antagonists, and in relation to withdrawal of medication
overuse. Furthermore there are important issues to be bet-
ter analysed in relation to management with onabotulinum-
toxinA over time, including optimal definition of de novo
non-responders to onabotulinumtoxinA and even more
challenging to decide when and how onabotulinumtoxinA
should be considered to be tapered off in the long term
management of initial responders.
Future research regarding the treatment of CM with
onabotulinumtoxinA may further improve the manage-
ment of this highly disabling disorder.
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